ALEXA’S DAILY RECOMMENDATIONHealthLife StyleWORLD

BIO-RAD: Antibodies To Prevent Hemorrhagic Fever Developed

Remember when Dr. Li-Meng Yan made that ominous warning about intelligence suggesting the CCP could potentially use the Winter Olympics as a vector for a hemorrhagic fever virus bioweapon?

Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender

According to Dr. Yan, “there is already a cure for this alleged bioweapon and the CCP wants to limit its availability as much as possible. It is a Johnson & Johnson drug called Darzalex (daratumumab). According to Cancer.org, the drug is currently used to treat multiple myeloma, but Dr. Yan said the CCP discovered it is also effective against their new bioweapons.”

A biopharmaceutical company called Bio-Rad has reportedly developed antibodies that inhibit daratumumab from binding to receptors in the body and stopping infection with hemorrhagic fever.

“Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars,” the journal The Scientist wrote in their scientific report.

What do you think about this, now?

Isn’t it suspicious that Bio-Rad would announce antibodies that inhibit the binding ability of the drug that, according to Dr. Li-Meng Yan, easily treats hemorrhagic fever?

Source
TwitterWe Love TrumpThe Scientist

Ava Garcia

A small town girl, dreaming big, expecting to change the world with presenting the truthful events of the world today. Law degree with a master in criminology, and a devoted journalist for over 7 years, and counting. "The pen is mightier than the sword."

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Back to top button

Adblock Detected

For continue reading on the site please disable the Ad-block